There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 4 | 59 | 1922.6 |
| 1 | 3 | 1922.1 |
| 1 | 6 | 1922 |
| 2 | 4 | 1921.9 |
| 2 | 3 | 1921.6 |
| Ask | Qty | Orders |
|---|---|---|
| 1924.1 | 2 | 5 |
| 1924.2 | 1 | 18 |
| 1924.4 | 3 | 104 |
| 1925 | 218 | 262 |
| 1925.2 | 1 | 20 |
Annual Revenue,rose 12.11%, in the last year to ₹2,864.18 Cr. Its sector's average revenue growth for the last fiscal year was 20.05%.Annual Net Profit,rose 3.62% in the last year to ₹504.78 Cr. Its sector's average net profit growth for the last fiscal year was -20.22%.Return on Equity(ROE),for the last financial year was 20.12%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.
Dr. Lal PathLabs Limited is a public company incorporated on February 14 1995. Its registered office at Block E, Sector-18, Rohini, New Delhi 110085 . The company traces its roots to 1949 and today provides a comprehensive menu of 5,000+ diagnostic tests and panels, including specialised and genomic testing, through a nationwide network of laboratories and service centres.
Its portfolio spans biochemistry, haematology, histopathology, microbiology, immunology, virology, cytology, electrophoresis, immuno-chemistry, and radiology investigations, alongside branded offerings such as Genevolve (genomics), L-CoRD (reproductive diagnostics) and L-ACE (autoimmune disorders), plus AI-enabled diagnostics and tech-enabled sample tracking . Dr. Lal PathLabs operates across India with international subsidiaries and labs in Nepal and Bangladesh, reflecting a Pan-India footprint with select overseas presence.
Key milestones include establishing Asia’s largest National Reference Lab in Delhi (2010), becoming the first Indian healthcare company to list via IPO (2015), launching the first COVID RT-PCR testing network in India’s private sector (2020), and subsequent expansions such as reference labs in Mumbai and Bengaluru and acquisitions like Suburban Diagnostics (2021) .
As of 03 Sep 2026, the share price of Dr Lal Pathlabs Ltd is ₹1,926.80 on the NSE and ₹1,924.60 on the BSE. The stock opened at ₹1,927.20, touched a high of ₹1,963.00 and a low of ₹1,873.80 during today's session.
Over the last 6 months, Dr Lal Pathlabs Ltd has given a return of 40.94%. The stock was priced at ₹1,405.90 on 02 Mar 2026 and has Rise to ₹1,926.80 as of 03 Sep 2026, a change of ₹520.90 per share.
For Q1 FY27, Dr Lal Pathlabs Ltd reported: Revenue (Net Sales): ₹7644.00 Cr - Up 13.21% year-on-year from ₹6752.00 Cr in Q4 FY26. Net Income (PAT): ₹1659.00 Cr - Up 17.58% year-on-year from ₹1411.00 Cr in Q4 FY26.
The intraday low for Dr Lal Pathlabs Ltd on the NSE today was ₹1,873.80. The stock's 52-week low stands at ₹1,272.60, recorded on 23 Mar 2026. Today's low is 47.24% above the 52-week low, indicating the stock is trading well above its yearly lows.
Dr Lal Pathlabs Ltd has delivered a return of 22.08% over the last 3 months. The stock was trading at ₹1,569.60 on 03 Jun 2026 and is currently at ₹1,926.80 as of 03 Sep 2026, reflecting a Gain of ₹357.20 per share over this period.
Dr Lal Pathlabs Ltd has delivered 14.82% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹1,988.90 on 12 Aug 2026 and a 52-week low of ₹1,272.60 on 23 Mar 2026. It is currently trading at ₹1,926.80 as of 03 Sep 2026.
The all-time high (ATH) for Dr Lal Pathlabs Ltd was ₹2,104.30, recorded on 15 Sep 2021. At the current price of ₹1,926.80, the stock is trading 8.44% below its all-time high. The all-time low recorded was ₹360.18 on 20 Jan 2016.
Dr Lal Pathlabs Ltd has delivered a -6.39% absolute return over the past 5 years, equivalent to a CAGR of -1.31% per annum. The stock was priced at ₹2,058.33 in Sep 2021 and has fallen to ₹1,926.80 as of 03 Sep 2026. An investment of ₹1,00,000 in Dr Lal Pathlabs Ltd five years ago would be worth ₹93,610.00 today.
Yes,Dr Lal Pathlabs Ltd has declared a consistent dividend every year over the past 5 years. The company paid a total dividend of 91.50 per share between FY2022 and FY2026, with the most recent dividend of ₹5.00 per share for Jul 26, with an ex-dividend date of 30 Jul 2026. At the current market price of ₹1,926.80, the trailing dividend yield of Dr Lal Pathlabs Ltd stands at 25.50%.
The intraday high for Dr Lal Pathlabs Ltd on the NSE today (03 Sep 2026) was ₹1,963.00. This compares to the 52-week high of ₹1,988.90 recorded on 12 Aug 2026. Today's high was -1.30% below the 52-week high.
